Option chain shows key data for Oculis Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oculis Holding.

Oculis Holding (NASDAQ:OCSAW) Stock, Option Chain

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG

On Tuesday, December 24th, U.S. markets closed higher in an abbreviated Christmas Eve session, driven by gains in megacap and growth stocks, marking a continued Santa Claus rally. The Dow and Nasdaq logged four-session gains, while Tesla&#8217;s surge boosted the consumer discretionary sector. Chipmakers like Broadcom and Arm Holdings also advanced despite elevated U.S. Treasury yields.
Every sector of the S&amp;P 500 ended in positive territory, led by notable gains in consumer discretionary, financial, and information technology stocks.
In economic data, the U.S. Redbook index rose 5.9% year-over-year last week, up from 4.8%. Meanwhile, the Fifth District composite manufacturing index improved to -10 in December from -14.
The Dow Jones Industrial Average was up 0.91% and closed at 43,297.03, the S&amp;P 500 closed higher by 1.10% at 6,040.00, and the Nasdaq Composite gained 1.35% to finish at 20,031.13.
Asia Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 gained 1.39% and ended the session at 39,578.00, led by gains in the Shipbuilding, Automobiles &amp; Parts, and Chemical, Petroleum &amp; Plastic sectors.</li>
<li>Australia markets closed for the Boxing Day holiday.</li>
<li>India&#8217;s Nifty 50 rose 0.16% to 22,438.20, and Nifty 500 was up 0.14%, closing at 23,761.95, led by gains in the Auto, Power, and Public Sector Undertakings sectors.</li>
<li>China&#8217;s Shanghai Composite rose 0.14% to close at 3,398.08, and the Shenzhen CSI 300 gained 0.05%, finishing the day at 3,987.48.</li>
<li>Hong Kong market closed for the first weekday after Christmas Day.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 closed for the Boxing Day holiday.</li>
<li>German markets closed for the Boxing Day holiday.</li>
<li>France&#8217;s CAC closed for the Boxing Day holiday.</li>
<li>U.K.&#8217;s FTSE 100 closed for the Boxing Day holiday.</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.61% at $70.53/bbl, and Brent was up 0.56% at $73.58/bbl.</li>
<li>Natural Gas fell 2.31% to $3.421.</li>
<li>Gold was trading higher by 0.36% at $2,645.09, Silver was up 0.19% to $30.340, and Copper rose 0.11% to $4.1147.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were down 0.36%, S&amp;P 500 futures declined 0.39%, and Nasdaq 100 futures slid 0.42%.
Forex at 06:00 AM ET
The U.S. Dollar Index was down 0.04% to 108.16. USD/JPY rose 0.03% to 157.45, and USD/AUD rose 0.14% to 1.6048.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

News

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asian Markets Up, Europe Closed; Dollar Hovers Near 2-Year High - Global Markets Today While US Slept

<a href="https://www.globenewswire.com/Tracker?data=MvoSLa0RdJ-p44BY3TZ25mYKru5_318w0rZMXr5aH6I0DqWabfIEqtY-P3Do4r-ha3Ixwnyb-TlA3geaSdd-igUkFxl2N0FLfz6qXlXQEgw=">Hyperscale Data, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("Hyperscale Data" or the "Company"), today announced the completion of a $50 million preferred equity investment, whereby the Company sold that dollar amount through the issuance to Ault &amp; Company, Inc. ("Ault and Company") of 50,000 shares of Series C Convertible Preferred Stock (the "Series C Shares").&nbsp;Ault &amp; Company&nbsp;has invested $50 million through multiple closings over the past thirteen (13) months. This strategic influx of capital has enabled Hyperscale Data to accelerate its growth trajectory, enhance its technological offerings, and execute its business expansion plans more effectively, with a focus on becoming a pure AI data center company. The Company would like to remind its stockholders that on March 25, 2024, the Company and Ault and Company agreed to raise the aggregate offering of Series C Shares from $50 million to $75 million. This offering is continuing apace, but the Company cannot assure you when Ault and Company will complete the remaining purchases of $25 million in Series C Shares, if at all.

GPUS

Hyperscale Data Secures $50M Investment, Eyes AI Data Center Growth

In addition to this significant investment, Hyperscale Data is strategically spinning out all of its non-data center and non-Bitcoin mining assets. This move is aimed at refining the Company's core focus and reinforcing its commitment to leading the AI-driven data center industry.
 &nbsp;

Hyperscale Data Closes $50M Of Aggregate $75M Preferred Equity Investment From Ault & Company; Says It Is Strategically Spinning Out All Of Its Non-Data Center And Non-Bitcoin Mining Assets

Meiwu Technology Regains Compliance With Nasdaq Listing Rule, Which Requires Ordinary Shares To Maintain Minimum Bid Price

Shares of&nbsp;MicroStrategy Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) dropped by 4.08% following the company&#8217;s announcement to issue more shares to finance additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions. This move aligns with MicroStrategy&#8217;s ongoing strategy to bolster its Bitcoin reserves.
What Happened: MicroStrategy&#8217;s recent filing&nbsp;with the U.S. Securities and&nbsp;Exchange Commission (SEC) aims to expand&nbsp;the authorized number of Class&nbsp;A&nbsp;common stock from 330 million&nbsp;to 10.33 billion units and&nbsp;preferred stock from 5 million&nbsp;to over 1 billion units.&nbsp;This move underscores the company&#8217;s transition from a software enterprise&nbsp;to a major Bitcoin investor.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/12/42664692/bitcoin-flat-ethereum-dogecoin-spike-ahead-of-christmas-analyst-says-decline-in-btc-dominance-leaves-room-for-altcoins-to-pick-up?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves &#8216;Room For Altcoins To Pick Up&#8217;</a>
The company recently acquired&nbsp;$561 million worth of Bitcoin,&nbsp;marking its seventh consecutive week&nbsp;of purchases, with total holdings now estimated at $40 billion. Despite Bitcoin&#8217;s 135% increase this year, market volatility is expected as $43 billion in&nbsp;Bitcoin and Ether derivatives are&nbsp;due to expire on Friday.
Meanwhile, Bitcoin Thursday during pre-market hours was trading at $95,621.41. The cryptocurrency briefly hit an intraday peak of $99,876.70. A broader cryptocurrency index, which includes tokens such as Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), also experienced a minor recovery, rising by 0.2%.
Why It Matters: MicroStrategy&#8217;s decision to issue more shares comes on the heels of its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire">recent inclusion in the Nasdaq 100</a>, which has not been without challenges. The company&#8217;s stock fell over 8.5% on its debut in the index, marking a difficult start to its tenure. Over the past month, MicroStrategy&#8217;s stock has plunged more than 37% from its all-time high, reflecting investor concerns over its aggressive Bitcoin strategy. The company&#8217;s recent sale of $561 million in common stock to purchase an additional 5,262 Bitcoins at an average price of $106,662 per coin has further intensified scrutiny.
The latest analyst ratings for MicroStrategy Inc were issued by Bernstein on Dec.12, and by both TD Cowen and Barclays on Nov. 25. These analysts, <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">tracked by Benzinga</a>, have set an average price target of $546.67, suggesting a potential upside of 58.01% for the stock.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26062848/Screenshot-2024-12-26-at-4.58.41%E2%80%AFPM-1024x364.png" alt="" class="wp-image-707471" /></figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42673114/bitcoins-outperformance-could-leave-dogecoin-shiba-inu-sidelined-but-propel-pepe-dogwifhat-bonk-to-new-highs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Outperformance Could Leave Dogecoin, Shiba Inu Sidelined, But Propel Pepe, Dogwifhat, Bonk To New Highs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

General

$BTC

$DOGE

$ETH

$SOL

MSTR

MicroStrategy Stock Tumbles Over 4% In Thursday Premarket: What's Going On?

Macro Economic Events

Econ #s

Economics

France Jobseekers Total For November 2,935.0K  Vs. 2,891.5K Prior

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and raises the price target from $40 to $42.

Price Target

Analyst Ratings

AVXL

HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Raises Price Target to $42

Chinese EV startup Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) launched its new lower-priced EV brand Onvo in May this year. The brand started selling its first vehicle- the Onvo L60- in late September and since then, Nio sales have been on the rise.
What Happened: The Onvo L60 is a mid-size electric SUV that starts at 206,900 yuan ($28,347) with the battery pack included, much lower than Tesla&#8217;s affordable models Model 3 or Model Y in China.
In September, Nio delivered 832 Onvo L60s despite having only a few selling days. In October, the first full month of sales, Onvo deliveries rose to 4,319. In November, L60 deliveries rose to 5,082, implying demand for the vehicle. 
In August, the month before Onvo deliveries commenced, Nio delivered 20,176 vehicles, marking a growth of just 4.4% year-on-year.
In September, the first month of Onvo L60 deliveries, Nio&#8217;s total deliveries jumped 35.4% as compared to the corresponding period last year. In October and November, deliveries <a href="https://www.benzinga.com/24/12/42260165/li-auto-xpeng-nio-heres-how-november-deliveries-of-chinese-ev-startups-stack-up">marked an increase of 30.5% and 29%</a>, respectively.
Why It Matters: Nio identifies itself as a premium EV brand. Its ET9, for instance, starts at 788,000 yuan, including the battery. 
The low-cost EV from the company&#8217;s Onvo brand has helped it move to the low-cost EV segment which has significant demand.
Earlier this month, Nio also <a href="https://www.benzinga.com/24/12/42550944/whats-going-on-with-nio-stock-today">launched a new brand called Firefly</a>, touted as a rival to Mercedes&#8217; Smart and BMW&#8217;s Mini. The brand&#8217;s first vehicle shares its name and pre-sales started at a price of 148,800 yuan. It is expected to be launched in April 2025.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: Nio

Tech

Nio's Onvo Brand Helps Spur Delivery Growth With Cheaper Offering

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy and lowers the price target from $14 to $11.

PYPD

HC Wainwright & Co. Maintains Buy on PolyPid, Lowers Price Target to $11

Raymond James analyst C. Gregory Peters maintains Kemper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) with a Strong Buy and raises the price target from $75 to $82.

KMPR

Raymond James Maintains Strong Buy on Kemper, Raises Price Target to $82

Earnings

NVNI

Nvni Group Reported FY23 Revenue Growth Of 36% YoY

SATS

Microelectronics Technology Enters Strategic Partnership With EchoStar To Advance Development Of Energy-Efficient Open RAN Macro Radios With NTIA Grant

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) from Neutral to Buy and maintains the price target from $10 to $10.

Upgrades

RAPT

HC Wainwright & Co. Upgrades RAPT Therapeutics to Buy, Maintains Price Target to $10

Demand for <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence-enabled</a> smartphones could serve as a buffer for parts of the semiconductor industry against a potential slowdown in data center investments, Financial Times <a target="_blank" href="https://www.ft.com/content/54c3d188-9c5d-4664-94c4-366207ef9aad" rel="noreferrer noopener">cites</a> Doug Lefever, CEO of Advantest, a Japanese supplier of chip testing equipment for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Lefever expressed concern over possible dips in spending by <a target="_blank" href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" rel="noreferrer noopener">major U.S. tech companies</a>, such as Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which have been driving the construction of advanced data centers.
Lefever told the FT that while fluctuations in data center spending may not last long, any decline could significantly disrupt the semiconductor supply chain due to its reliance on hyperscalers.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42675098/netflix-takes-vmware-to-court-over-patent-infringement-claims" rel="noreferrer noopener">Broadcom and Netflix Clash Over Patent Disputes Ahead of 2025 Trial</a>
He added that the industry&#8217;s cyclical nature could lead to what he described as &#8220;vicious&#8221; downturns. However, he remained optimistic about the potential growth of AI smartphones, suggesting that a breakthrough application could rapidly drive consumer demand and spark a wave of handset replacements.
Advantest, headquartered in Tokyo, holds over 50% of the semiconductor testing market and has benefited from the rising complexity and cost of chips.
Lefever highlighted the growing complexity of chip testing, with Nvidia&#8217;s latest Blackwell products requiring three to four times longer to test than previous generations, as a key driver of sustained demand for Advantest&#8217;s solutions.
The company&#8217;s success extends to high-end testing equipment, which costs $1 million per unit and boasts a market share exceeding 60% in specific categories. Despite geopolitical challenges, such as U.S. restrictions on China, Lefever told the FT that increased demand elsewhere quickly offset lost sales in China. He emphasized that Advantest remains well-positioned globally, with operations in 18 countries and a diversified customer base.
Apple began introducing its <a target="_blank" href="https://www.benzinga.com/news/24/10/41526650/apples-ai-powered-future-iphone-growth-surge-by-2026-with-new-iphone-17-ai-integration-analyst-says" rel="noreferrer noopener">Apple Intelligence features</a> on October 28 with the launch of iOS 18.1, offering initial AI functionalities.
The rollout will continue with iOS 18.2, including ChatGPT integration and advanced tools like Visual Intelligence and Genmoji, aiming to boost future sales.
Needham&nbsp;analyst Laura Martin expects Apple iPhone to account for up to 96% of the <a target="_blank" href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro" rel="noreferrer noopener">company&#8217;s 2025 revenue</a>.
International Data Corporation (IDC) had <a target="_blank" href="https://www.benzinga.com/news/24/08/40600289/apples-market-share-poised-to-gain-genai-and-iphone-16-lead-the-way-idc" rel="noreferrer noopener">reignited confidence in</a> smartphone manufacturers, including Apple, with a new market forecast projecting a 5.8% rise in global smartphone shipments to 1.23 billion units in 2024, recovering after two tough years.
The report highlighted increased demand for budget Android smartphones in China and emerging markets and strong adoption of generative AI smartphones in premium markets as key growth drivers.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42672262/hive-digital-boosts-ai-ambitions-with-30-million-nvidia-gpu-deployment" target="_blank" rel="noreferrer noopener">HIVE Digital Boosts AI Ambitions With $30 Million Nvidia GPU Deployment</a></li>
</ul>
Image via Shutterstock.

Media

GOOG

GOOGL

MSFT

NVDA

AI Smartphones To Cushion Semiconductor Industry Amid Data Center Uncertainty: Report

This appointment not only introduces strong leadership to Color Star but also strengthens the company's ties with the Middle East, particularly the UAE.

Management

Reported Earlier, Color Star Technology Says Shaikh Humaid Abdulla Rashed Ahmed Almualla, A Prominent Member Of The UAE Royal Family, Has Joined As An Independent Director

HC Wainwright &amp; Co. analyst Andrew Fein initiates coverage on Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy rating and announces Price Target of $38.

Initiation

PVLA

HC Wainwright & Co. Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $38

Raymond James analyst C. Gregory Peters downgrades Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) from Market Perform to Underperform.

Downgrades

HGTY

Raymond James Downgrades Hagerty to Underperform

Needham analyst Chris Pierce maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $26 to $28.

ACVA

Needham Maintains Buy on ACV Auctions, Raises Price Target to $28

Raymond James analyst Aaron Kessler upgrades EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) from Outperform to Strong Buy and maintains the price target from $35 to $35.

EVER

Raymond James Upgrades EverQuote to Strong Buy, Maintains Price Target to $35

Raymond James analyst C. Gregory Peters upgrades Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from Market Perform to Outperform and announces $305 price target.

Raymond James Upgrades Progressive to Outperform, Announces $305 Price Target

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Oculis Holding

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Oculis Holding

Oculis Holding (OCSAW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga